Related Experiment Video

Updated: Oct 16, 2025

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.2K

Combination therapy with miR-34a and doxorubicin synergistically induced apoptosis in T-cell acute lymphoblastic

Shiva Najjary1,2, Reza Mohammadzadeh3, Behzad Mansoori1,4

  • 1Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Medical Oncology (Northwood, London, England)
|October 16, 2021
PubMed

Insights

Restoring tumor suppressor microRNAs (miRNAs) like miR-34a can fight cancer. Combining miR-34a with doxorubicin chemotherapy enhances cancer cell death and apoptosis in T-cell leukemia.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) play crucial roles in cancer development, with reduced tumor suppressor miRNA expression often promoting cancer.
  • Single-drug therapies face challenges due to cancer cell heterogeneity and drug resistance.
  • Combining chemotherapy with miRNA-based therapies presents a promising strategy for overcoming resistance and improving treatment efficacy.

Purpose of the Study:

  • To investigate the synergistic effects of miR-34a mimic in combination with doxorubicin on acute T-cell lymphoblastic leukemia (T-ALL) Jurkat cells.
  • To evaluate the impact of this combination therapy on apoptosis-related gene expression, cell viability, and cell cycle progression.
  • To determine if miR-34a enhances the sensitivity of Jurkat cells to doxorubicin treatment.

Main Methods:

  • Transfection of Jurkat cells with miR-34a mimic and negative control using jetPEI reagent.
  • Assessment of synergistic effects using MTT assay for cell viability and flow cytometry/DAPI staining for apoptosis.
  • Analysis of apoptosis-related gene expression, including Caspase-3, Bcl-2, and p53.
  • Cell cycle analysis to detect G2/M phase arrest.

Main Results:

  • The combination of miR-34a and doxorubicin significantly reduced Bcl-2 gene expression, a known target of miR-34a.
  • MTT assays showed a significant decrease in Jurkat cell survival rates compared to untreated controls.
  • Flow cytometry and DAPI staining confirmed an increased apoptosis rate in cells treated with the combination therapy.
  • Cell cycle analysis revealed arrest at the G2/M phase following miR-34a/doxorubicin treatment.
  • Transfection with miR-34a increased Jurkat cell sensitivity to doxorubicin.

Conclusions:

  • The combination of miR-34a and doxorubicin demonstrates significant synergistic effects in inducing apoptosis and reducing viability in T-ALL Jurkat cells.
  • This combination therapy enhances the sensitivity of T-ALL cells to doxorubicin, suggesting a potential strategy to overcome drug resistance.
  • miR-34a/doxorubicin treatment effectively promotes apoptosis and causes cell cycle arrest, offering a promising therapeutic approach for T-cell acute lymphoblastic leukemia.
Keywords:
ApoptosisDoxorubicinT-cell acute lymphoblastic leukemia (T-ALL)miR-34a

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
740